Physician profile
Benjamin Jon Marengo
NPI 1912434614
$2,113.37
in general payments reported to CMS, 2019-2025
22 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $118 · 2021: $119 · 2022: $296 · 2023: $228 · 2024: $355 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $493.28 | 2020-2025 | Lifevest |
| Novo Nordisk INC | $238.47 | 2021-2022 | |
| Amgen INC. | $161.74 | 2022-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $129.45 | 2025 | |
| Janssen Scientific Affairs, LLC | $123.98 | 2019 | |
| Vifor Pharma, INC. | $121.84 | 2019 | |
| Boston Scientific Corporation | $115.06 | 2020-2023 | Watchman Flx |
| Pfizer INC. | $112.94 | 2024-2025 | |
| Medtronic, INC. | $107.10 | 2022 | |
| Scpharmaceuticals INC. | $85.54 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $71.83 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.57 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $50.67 | 2025 | Keytruda, Verquvo |
| Lantheus Medical Imaging, INC. | $43.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $32.16 | 2023-2025 | Farxiga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $31.07 | 2024 | Zio Monitor, Zio Xt Patch |
| Abiomed | $28.63 | 2024 | Impella |
| Atricure, INC. | $28.54 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Atricure Cryoice Cryosphere Cryoablation System |
| Bridgebio Pharma, INC. | $28.49 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $23.21 | 2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $13.88 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Marengo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.